Connect Biopharma will present two new analyses of rademikibart, its anti–IL-4Rα monoclonal antibody, at the European Respiratory Society Congress 2025 in Amsterdam. The posters focus on moderate-to-severe asthma, examining how eosinophil counts, FeNO, and regional variability correlate with response, and highlighting rapid and sustained FEV1 improvements. Both will be showcased in the biologics session on September 29, with materials subsequently posted to the company’s website.
The strategic question is whether a second IL-4Rα entrant can carve meaningful space in a market anchored by an entrenched class leader. Mechanism familiarity reduces scientific risk, but it raises a higher bar for differentiation. If the ERS data show faster lung function gains, clearer biomarker-defined responders, or advantages in real-world relevant endpoints such as exacerbation reduction and steroid sparing, rademikibart could be positioned not merely as a class alternative but as a precision option within Type 2 inflammation.
This matters now because respiratory immunology is in flux. Biologics have moved from niche add-ons to the center of severe asthma and are expanding into COPD with biomarker-guided targeting. Payers are increasingly codifying eosinophils and FeNO into criteria, which puts a premium on evidence that links baseline biology to outcomes. Analyses that parse response by eosinophil strata and FeNO are not just academic; they are the scaffolding for payer negotiations, guideline inclusion, and HCP adoption pathways. If Rademikibart can demonstrate consistent efficacy across regions, that also addresses a perennial obstacle in global development: heterogeneity in background care, phenotypes, and practice patterns that can dilute effect sizes and complicate label and pricing strategies.
For patients and HCPs, the immediate relevance is pragmatic. Rapid FEV1 improvement can influence initiation in uncontrolled patients and may support earlier biologic use, especially when exacerbation risk is high. For hospital systems and payers, Connect’s stated focus on acute exacerbations of asthma and COPD aims at high-cost events where even modest absolute risk reductions can be economically compelling. If the program ultimately documents impact in the acute-care window, it could open a new deployment model for respiratory biologics that prioritizes prevention of readmissions and systemic steroid exposure.
Competitively, the bar is rising. The IL-4/IL-13 axis is validated in asthma and now in biomarker-selected COPD, while upstream and adjacent mechanisms such as TSLP and IL-5 continue to fragment the market by phenotype. Any advantage Rademikibart shows on speed of effect, dosing convenience, or exacerbation-related endpoints will need to be demonstrated with enough robustness to counteract inertia around existing standards. Without head-to-head data, Medical Affairs will be pressed to deliver high-quality indirect comparisons, pragmatic studies, and RWE that resonate with guideline bodies and integrated delivery networks.
Commercially, scale and capital matter. Connect’s collaboration with Simcere in China suggests a partnering mindset; ex-China strategy will likely hinge on whether forthcoming data can justify either regional alliances or a focused launch in clearly defined biomarker segments. Pricing power in a follow-on mechanism will be tightly linked to demonstrable differentiation and the ability to integrate biomarker testing into routine care without operational friction.
The signal to watch at ERS is not only whether rademikibart works, but how it works across biomarker thresholds, care settings, and geographies—because in a crowded respiratory class, the winning story will be precision, speed, and practical impact on exacerbations rather than mechanism alone.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
